Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia
Status:
Unknown status
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Patients with advanced chronic lymphocytic leukemia (CLL) have a poor long-term prognosis.
Allogeneic stem cell transplantation (SCT) in patients with CLL has only rarely been
performed in the past because the clinical outcome after myeloablative conditioning was poor,
mainly due to the high treatment-related mortality. However long-term disease-free survival
after allogeneic SCT has been reported. Recently it has been demonstrated by our group and
others that non-relapse mortality can be reduced significantly with the use of
reduced-intensity conditioning regimens. Yet, graft versus host disease (GVHD) remains an
important problem in this setting.
Alemtuzumab is an effective drug for the treatment of patients with advanced CLL and has been
successfully applied for GVHD-prophylaxis in the setting of myeloablative and
reduced-intensity conditioning regimens. The goal of the present study is to evaluate the
role of alemtuzumab as part of a fludarabine-based reduced intensity conditioning regimen for
allogeneic SCT in patients with advanced CLL.
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborators:
Deutsche Klinik fuer Diagnostik University Hospital Carl Gustav Carus